Clinical Report: Counseling Patients About Gene Therapy

Overview

This report discusses the importance of counseling patients about gene therapy for inherited retinal diseases (IRDs), emphasizing the need for realistic expectations regarding eligibility and outcomes. It highlights the complexities of genetic testing and the role of healthcare providers in guiding patients through the treatment landscape.

Background

Gene therapy represents a significant advancement in the treatment of inherited retinal diseases, with the first FDA-approved therapy, Luxturna, targeting specific genetic mutations. As new therapies emerge, it is crucial for patients to receive accurate information to make informed decisions about their treatment options. The complexity of genetic testing and varying eligibility criteria necessitate comprehensive counseling to support patient understanding and decision-making.

Data Highlights

No numerical data available in the source material.

Key Findings

• Gene therapy can change the treatment landscape for inherited retinal diseases.
• Eligibility for gene therapy often depends on specific genetic criteria, such as the presence of biallelic pathogenic variants.
• Patients may encounter exaggerated claims about gene therapy through media, necessitating balanced information from healthcare providers.
• Genetic counseling is essential for interpreting test results and determining treatment eligibility.
• Advanced disease stages may limit eligibility for certain gene therapies due to the requirement for viable retinal cells.

Clinical Implications

Healthcare providers must ensure that patients are well-informed about the complexities of gene therapy, including eligibility criteria and potential outcomes. Establishing realistic expectations can enhance patient experience and support informed decision-making.

Conclusion

Effective counseling about gene therapy is vital for patients with inherited retinal diseases, as it helps them navigate treatment options and align decisions with their personal values and health goals.

References

1. Counseling Patients About Gene Therapy | Retinal Physician, 2025 -- Counseling Patients About Gene Therapy
2. Introduction to gene therapy, Ophthalmic Professional, 2020 -- Introduction to gene therapy
3. Navigating the Ethics of Self-Experimentation in Gene Therapy, Brain, 2020 -- Navigating the Ethics of Self-Experimentation in Gene Therapy: Finding the Right Approach
4. Should Restrictions on Genetic Testing Be Loosened?, The ASCO Post, 2020 -- Should Restrictions on Genetic Testing Be Loosened?
5. The Inherited Retinal Disease Pipeline, Review of Ophthalmology, 2025 -- The Inherited Retinal Disease Pipeline
6. Efficacy and Safety of Gene Therapy for RPGR Gene-Associated X-Linked Retinitis Pigmentosa: A Systematic Review and Meta-Analysis - PMC, 2023 -- Efficacy and Safety of Gene Therapy for RPGR Gene-Associated X-Linked Retinitis Pigmentosa
7. The Inherited Retinal Disease Pipeline
8. Efficacy and Safety of Gene Therapy for RPGR Gene-Associated X-Linked Retinitis Pigmentosa: A Systematic Review and Meta-Analysis - PMC
9. Counseling Patients About Gene Therapy | Retinal Physician